The Post-Myocardial Infarction drugs in development market research report provides comprehensive information on the therapeutics under development for Post-Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post-Myocardial Infarction. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post-Myocardial Infarction and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Post-Myocardial Infarction by eight companies/universities/institutes. The top development phase for Post-Myocardial Infarction is preclinical with five drugs in that stage. The Post-Myocardial Infarction pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Post-Myocardial Infarction pipeline products market are: HUYA Bioscience International, Biogen and Novartis.
The key targets in the Post-Myocardial Infarction pipeline products market include Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I/Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprotein PC1 or ENPP1 or EC 3.1.4.1 or EC 3.6.1.9), Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5), and Type 1 Angiotensin II Receptor (AT1AR or AT1BR or Angiotensin II Type 1 Receptor or AGTR1).
The key mechanisms of action in the Post-Myocardial Infarction pipeline product include Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5) Inhibitor with one drug in Phase II. The Post-Myocardial Infarction pipeline products include three routes of administration with the top ROA being Intravesical and five key molecule types in the Post-Myocardial Infarction pipeline products market including Small Molecule, and Cell Therapy.
Post-Myocardial Infarction overview
After myocardial infarction (MI), patients are at a greater risk of heart failure. This happens when blood flow to the heart muscle is blocked. Long-term beta-blocker use after MI is associated with a reduced risk of reinfarction and death. Thus, it is critical to frequently re-evaluate beta-blocker eligibility among patients after MI with HF.
For a complete picture of Post-Myocardial Infarction’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
